Regeneron Pharmaceuticals Inc

NASDAQ REGN

Data sourced from

and

Daily

Download Data

Regeneron Pharmaceuticals Inc Price to Earnings Ratio (P/E) on June 03, 2024: 110.73

Regeneron Pharmaceuticals Inc Price to Earnings Ratio (P/E) is 110.73 on June 03, 2024, a 476.37% change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.

Regeneron Pharmaceuticals Inc 52-week high Price to Earnings Ratio (P/E) is 111.23 on May 21, 2024, which is 0.45% above the current Price to Earnings Ratio (P/E).
Regeneron Pharmaceuticals Inc 52-week low Price to Earnings Ratio (P/E) is 17.25 on July 07, 2023, which is -84.42% below the current Price to Earnings Ratio (P/E).
Regeneron Pharmaceuticals Inc average Price to Earnings Ratio (P/E) for the last 52 weeks is 41.39.

NASDAQ: REGN

Regeneron Pharmaceuticals Inc

CEO	Dr. Leonard S. Schleifer M.D., Ph.D.
IPO Date	April 2, 1991
Location	United States
Headquarters	777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
Employees	13,677
Sector	Healthcare
Industry	Biotechnology

Description

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Key trends